Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.

The factors influencing three major outcomes-death, stroke/systemic embolism (SE), and major bleeding-have not been investigated in a large international cohort of unselected patients with newly diagnosed atrial fibrillation (AF).In 28,628 patients prospectively enrolled in the GARFIELD-AF registry...

Full description

Bibliographic Details
Main Authors: Jean-Pierre Bassand, Gabriele Accetta, Wael Al Mahmeed, Ramon Corbalan, John Eikelboom, David A Fitzmaurice, Keith A A Fox, Haiyan Gao, Samuel Z Goldhaber, Shinya Goto, Sylvia Haas, Gloria Kayani, Karen Pieper, Alexander G G Turpie, Martin van Eickels, Freek W A Verheugt, Ajay K Kakkar, GARFIELD-AF Investigators
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5784935?pdf=render
id doaj-75beec487231485fb194868fd5e970bb
record_format Article
spelling doaj-75beec487231485fb194868fd5e970bb2020-11-25T01:22:52ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01131e019159210.1371/journal.pone.0191592Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.Jean-Pierre BassandGabriele AccettaWael Al MahmeedRamon CorbalanJohn EikelboomDavid A FitzmauriceKeith A A FoxHaiyan GaoSamuel Z GoldhaberShinya GotoSylvia HaasGloria KayaniKaren PieperAlexander G G TurpieMartin van EickelsFreek W A VerheugtAjay K KakkarGARFIELD-AF InvestigatorsThe factors influencing three major outcomes-death, stroke/systemic embolism (SE), and major bleeding-have not been investigated in a large international cohort of unselected patients with newly diagnosed atrial fibrillation (AF).In 28,628 patients prospectively enrolled in the GARFIELD-AF registry with 2-year follow-up, we aimed at analysing: (1) the variables influencing outcomes; (2) the extent of implementation of guideline-recommended therapies in comorbidities that strongly affect outcomes. Median (IQR) age was 71.0 (63.0 to 78.0) years, 44.4% of patients were female, median (IQR) CHA2DS2-VASc score was 3.0 (2.0 to 4.0); 63.3% of patients were on anticoagulants (ACs) with or without antiplatelet (AP) therapy, 24.5% AP monotherapy, and 12.2% no antithrombotic therapy. At 2 years, rates (95% CI) of death, stroke/SE, and major bleeding were 3.84 (3.68; 4.02), 1.27 (1.18; 1.38), and 0.71 (0.64; 0.79) per 100 person-years. Age, history of stroke/SE, vascular disease (VascD), and chronic kidney disease (CKD) were associated with the risks of all three outcomes. Congestive heart failure (CHF) was associated with the risks of death and stroke/SE. Smoking, non-paroxysmal forms of AF, and history of bleeding were associated with the risk of death, female sex and heavy drinking with the risk of stroke/SE. Asian race was associated with lower risks of death and major bleeding versus other races. AC treatment was associated with 30% and 28% lower risks of death and stroke/SE, respectively, compared with no AC treatment. Rates of prescription of guideline-recommended drugs were suboptimal in patients with CHF, VascD, or CKD.Our data show that several variables are associated with the risk of one or more outcomes, in terms of death, stroke/SE, and major bleeding. Comprehensive management of AF should encompass, besides anticoagulation, improved implementation of guideline-recommended therapies for comorbidities strongly associated with outcomes, namely CHF, VascD, and CKD.ClinicalTrials.gov NCT01090362.http://europepmc.org/articles/PMC5784935?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Jean-Pierre Bassand
Gabriele Accetta
Wael Al Mahmeed
Ramon Corbalan
John Eikelboom
David A Fitzmaurice
Keith A A Fox
Haiyan Gao
Samuel Z Goldhaber
Shinya Goto
Sylvia Haas
Gloria Kayani
Karen Pieper
Alexander G G Turpie
Martin van Eickels
Freek W A Verheugt
Ajay K Kakkar
GARFIELD-AF Investigators
spellingShingle Jean-Pierre Bassand
Gabriele Accetta
Wael Al Mahmeed
Ramon Corbalan
John Eikelboom
David A Fitzmaurice
Keith A A Fox
Haiyan Gao
Samuel Z Goldhaber
Shinya Goto
Sylvia Haas
Gloria Kayani
Karen Pieper
Alexander G G Turpie
Martin van Eickels
Freek W A Verheugt
Ajay K Kakkar
GARFIELD-AF Investigators
Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.
PLoS ONE
author_facet Jean-Pierre Bassand
Gabriele Accetta
Wael Al Mahmeed
Ramon Corbalan
John Eikelboom
David A Fitzmaurice
Keith A A Fox
Haiyan Gao
Samuel Z Goldhaber
Shinya Goto
Sylvia Haas
Gloria Kayani
Karen Pieper
Alexander G G Turpie
Martin van Eickels
Freek W A Verheugt
Ajay K Kakkar
GARFIELD-AF Investigators
author_sort Jean-Pierre Bassand
title Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.
title_short Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.
title_full Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.
title_fullStr Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.
title_full_unstemmed Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.
title_sort risk factors for death, stroke, and bleeding in 28,628 patients from the garfield-af registry: rationale for comprehensive management of atrial fibrillation.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2018-01-01
description The factors influencing three major outcomes-death, stroke/systemic embolism (SE), and major bleeding-have not been investigated in a large international cohort of unselected patients with newly diagnosed atrial fibrillation (AF).In 28,628 patients prospectively enrolled in the GARFIELD-AF registry with 2-year follow-up, we aimed at analysing: (1) the variables influencing outcomes; (2) the extent of implementation of guideline-recommended therapies in comorbidities that strongly affect outcomes. Median (IQR) age was 71.0 (63.0 to 78.0) years, 44.4% of patients were female, median (IQR) CHA2DS2-VASc score was 3.0 (2.0 to 4.0); 63.3% of patients were on anticoagulants (ACs) with or without antiplatelet (AP) therapy, 24.5% AP monotherapy, and 12.2% no antithrombotic therapy. At 2 years, rates (95% CI) of death, stroke/SE, and major bleeding were 3.84 (3.68; 4.02), 1.27 (1.18; 1.38), and 0.71 (0.64; 0.79) per 100 person-years. Age, history of stroke/SE, vascular disease (VascD), and chronic kidney disease (CKD) were associated with the risks of all three outcomes. Congestive heart failure (CHF) was associated with the risks of death and stroke/SE. Smoking, non-paroxysmal forms of AF, and history of bleeding were associated with the risk of death, female sex and heavy drinking with the risk of stroke/SE. Asian race was associated with lower risks of death and major bleeding versus other races. AC treatment was associated with 30% and 28% lower risks of death and stroke/SE, respectively, compared with no AC treatment. Rates of prescription of guideline-recommended drugs were suboptimal in patients with CHF, VascD, or CKD.Our data show that several variables are associated with the risk of one or more outcomes, in terms of death, stroke/SE, and major bleeding. Comprehensive management of AF should encompass, besides anticoagulation, improved implementation of guideline-recommended therapies for comorbidities strongly associated with outcomes, namely CHF, VascD, and CKD.ClinicalTrials.gov NCT01090362.
url http://europepmc.org/articles/PMC5784935?pdf=render
work_keys_str_mv AT jeanpierrebassand riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT gabrieleaccetta riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT waelalmahmeed riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT ramoncorbalan riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT johneikelboom riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT davidafitzmaurice riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT keithaafox riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT haiyangao riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT samuelzgoldhaber riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT shinyagoto riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT sylviahaas riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT gloriakayani riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT karenpieper riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT alexanderggturpie riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT martinvaneickels riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT freekwaverheugt riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT ajaykkakkar riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
AT garfieldafinvestigators riskfactorsfordeathstrokeandbleedingin28628patientsfromthegarfieldafregistryrationaleforcomprehensivemanagementofatrialfibrillation
_version_ 1725125160779907072